Guideline for investigation and management of adults and children presenting with a thrombocytosis

British Journal of Haematology

Volumn 149, Issue 3, 2010, Pages 352-375

  Harrison, Claire N ^a   Bareford, David ^b   Butt, Nauman ^c   Campbell, Peter ^d   Conneally, Eibhlean ^e   Drummond, Mark ^f   Erber, Wendy ^g   Everington, Tamara ^h   Green, Anthony R ⁱ   Hall, Georgina W ^j   Hunt, Beverley J ^a   Ludlam, Christopher A ^k   Murrin, Richard ^l   Nelson Piercy, Catherine ^a   Radia, Deepti H ^a   Reilly, John T ^m   Van Der Walt, Jon ^a   Wilkins, Bridget ^a   McMullin, Mary F ⁿ  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c ARROWE PARK HOSPITAL   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e ST JAMES S HOSPITAL   (Ireland)

^f GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^k ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^l SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^m ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁿ BELFAST CITY HOSPITAL   (United Kingdom)

more..

Author keywords

Essential thrombocythaemia; MDS; Myelofibrosis; Myeloproliferative disorder

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BUSULFAN; CARBOQUONE; CHLORAMBUCIL; CLOPIDOGREL; ENOXAPARIN; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHORUS; PHOSPHORUS 32; PIPOBROMAN; PLACEBO; PRASUGREL; PREDNISONE; PYRIMETHAMINE; RANIMUSTINE; THIOTEPA; UNINDEXED DRUG; URAMUSTINE; WARFARIN;

5Q- SYNDROME; ACTINIC KERATOSIS; ALOPECIA; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; AZOOSPERMIA; BLAST CELL CRISIS; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CARCINOGENICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; LEG ULCER; LEUKEMIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG DYSPLASIA; LUNG FIBROSIS; LUNG TOXICITY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAIL DISEASE; NAIL DYSTROPHY; NAUSEA; NONHUMAN; PHLEBOTOMY; PNEUMONIA; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PREGNANCY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REPEATED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; TERATOGENICITY; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING;

ADULT; ALGORITHMS; CHILD; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; MYELODYSPLASTIC SYNDROMES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; MYELOPROLIFERATIVE DISORDERS; RISK ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOSIS;

EID: 77950809860     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08122.x     Document Type: Review

References (131)

1. Baglin, T., Luddington, R., Brown, K. Baglin, C. (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet, 362, 523 526.
2. Bain, B.J. (2005) Bone marrow biopsy morbidity: review of 2003. Journal of Clinical Pathology, 58, 406 408.
3. Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G. Tura, S. (1999) The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 104, 730 737.
4. Barosi, G., Besses, C., Birgegard, G., Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J.T., Michiels, J.J. Barbui, T. (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia, 21, 277 280.
5. Bayley, D., Temple, C., Clay, V., Steward, A. Lowther, N. (1995) The transmucosal absorption of recombinant human interferon-alpha B/D hybrid in the rat and rabbit. Journal of Pharmacy and Pharmacology, 47, 721 724.
6. Beer, P.A., Campbell, P.J., Scott, L.M., Bench, A.J., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Hasselbalch, H.C., Bowman, R., Wheatley, K., Buck, G., Harrison, C.N. Green, A.R. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 112, 141 149.
7. Belay, E.D., Bresee, J.S., Holman, R.C., Khan, A.S., Shahriari, A. Schonberger, L.B. (1999) Reye's syndrome in the United States from 1981 through 1997. New England Journal of Medicine, 340, 1377 1382.
8. van den Berghe, H., Cassiman, J.J., David, G., Fryns, J.P., Michaux, J.L. Sokal, G. (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature, 251, 437 438.
9. Berk, P.D., Goldberg, J.D., Donovan, P.B., Fruchtman, S.M., Berlin, N.I. Wasserman, L.R. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132 143.
10. Besses, C., Cervantes, F., Pereira, A., Florensa, L., Sole, F., Hernandez-Boluda, J.C., Woessner, S., Sans-Sabrafen, J., Rozman, C. Montserrat, E. (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150 154.
11. Bidot, C.J., Jy, W., Horstman, L.L., Ahn, E.R., Bidot, L., Fontana, V. Ahn, Y.S. (2005) Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. Hematology, 10, 451 456.
12. Boissinot, M., Garand, R., Hamidou, M. Hermouet, S. (2006) The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood, 108, 1781 1782.
13. Bowcock, S.J., Linch, D.C., Machin, S.J. Stewart, J.W. (1987) Pyrimethamine in the myeloproliferative disorders: a forgotten treatment? Clinical and Laboratory Haematology, 9, 129 136.
14. Breccia, M., Biondo, F., Latagliata, R., Carmosino, I., Mandelli, F. Alimena, G. (2006) Identification of risk factors in atypical chronic myeloid leukemia. Haematologica, 91, 1566 1568.
15. Budde, U., Schaefer, G., Mueller, N., Egli, H., Dent, J., Ruggeri, Z. Zimmerman, T. (1984) Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood, 64, 981 985.
16. Buss, D.H., Stuart, J.J. Lipscomb, G.E. (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. American Journal of Hematology, 20, 365 372.
17. Buss, D.H., Cashell, A.W., O'Connor, M.L., Richards, F. Case, L.D. (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. American Journal of Medicine, 96, 247 253.
18. Campbell, P.J. Green, A.R. (2006) The long-term outlook for essential thrombocythemia. Mayo Clinic Proceedings, 81, 157 158.
19. Campbell, P.J., Bareford, D., Erber, W.N., Wilkins, B.S., Wright, P., Buck, G., Wheatley, K., Harrison, C.N. Green, A.R. (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Journal of Clinical Oncology, 27, 2991 2999.
20. Carobbio, A., Antonioli, E., Guglielmelli, P., Vannucchi, A.M., Delaini, F., Guerini, V., Finazzi, G., Rambaldi, A. Barbui, T. (2008a) Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of Clinical Oncology, 26, 2732 2736.
21. Carobbio, A., Finazzi, G., Antonioli, E., Guglielmelli, P., Vannucchi, A.M., Delaini, F., Guerini, V., Ruggeri, M., Rodeghiero, F., Rambaldi, A. Barbui, T. (2008b) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 2. Blood, 112, 3135 3137.
22. Carroll, A.J., Poon, M.C., Robinson, N.C. Crist, W.M. (1986) Sideroblastic anemia associated with thrombocytosis and a chromosome 3 abnormality. Cancer Genetics and Cytogenetics, 22, 183 187.
23. Case, Jr., D.C. (1984) Therapy of essential thrombocythemia with thiotepa and chlorambucil. Blood, 63, 51 54.
24. Cervera, J.S., Mena-Duran, A.V. Piqueras, C.S. (2005) The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thrombosis and Haemostasis, 93, 383 384.
25. Christoforidou, A., Pantelidou, D., Anastasiadis, A., Goutzouvelidis, A., Margaritis, D., Kotsianidis, I., Spanoudakis, E., Kaloutsi, V., Bourikas, G. Tsatalas, C. (2008) Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta Haematologica, 120, 195 198.
26. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology, 8, 556 562.
27. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk thrombosis. New England Journal of Medicine, 332, 1132 1136.
28. D'adda, M., Micheletti, M., Drera, M., Ferrari, S. Rossi, G. (2008) The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Leukaemia & Lymphoma, 49, 2216 2218.
29. Dahabreh, I.J., Zoi, K., Giannouli, S., Zoi, C., Loukopoulos, D. Voulgarelis, M. (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia Leukemia Research, 33, 67 73.
30. Dame, C. Sutor, A.H. (2005) Primary and secondary thrombocytosis in childhood. British Journal of Haematology, 129, 165 177.
31. De Sanctis, V., Mazzucconi, M.G., Spadea, A., Alfo, M., Mancini, M., Bizzoni, L., Peraino, M. Mandelli, F. (2003) Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. British Journal of Haematology, 123, 517 521.
32. Ebert, B.L., Pretz, J., Bosco, J., Chang, C.Y., Tamayo, P., Galili, N., Raza, A., Root, D.E., Attar, E., Ellis, S.R. Golub, T.R. (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 451, 335 339.
33. Fend, F., Horn, T., Koch, I., Vela, T. Orazi, A. (2008) Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leukemia Research, 32, 1931 1935.
34. Finazzi, G. Barbui, T. (2001) Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathologie-biologie, 49, 167 169.
35. Finazzi, G., Ruggeri, M., Rodeghiero, F. Barbui, T. (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 101, 3749.
36. Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G. Barbui, T. (2005) Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood, 105, 2664 2670.
37. Gangat, N., Wolanskyj, A.P., Schwager, S.M., Mesa, R.A. Tefferi, A. (2006) Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer, 106, 2406 2411.
38. Gangat, N., Wolanskyj, A.P., Schwager, S. Tefferi, A. (2009) Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. European Journal of Haematology, 82, 350 353.
39. Giagounidis, A., Fenaux, P., Mufti, G.J., Muus, P., Platzbecker, U., Sanz, G., Cripe, L., Von Lilienfeld-Toal, M. Wells, R.A. (2008) Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of Hematology, 87, 345 352.
40. Gianelli, U., Vener, C., Raviele, P.R., Moro, A., Savi, F., Annaloro, C., Somalvico, F., Radaelli, F., Franco, V. Deliliers, G.L. (2006) Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology Leukaemia & Lymphoma, 47, 1774 1781.
41. Greaves, M., Cohen, H., Machin, S.J. Mackie, I. (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology, 109, 704 715.
42. Greer, I.A. Nelson-Piercy, C. (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 106, 401 407.
43. Griesshammer, M., Bergmann, L. Pearson, T. (1998) Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clinical Haematology, 11, 859 874.
44. Grigg, A.P., Gascoyne, R.D., Phillips, G.L. Horsman, D.E. (1993) Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. British Journal of Haematology, 83, 158 165.
45. Gupta, R., Abdalla, S.H. Bain, B.J. (1999) Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leukaemia & Lymphoma, 34, 615 619.
46. Hanft, V.N., Fruchtman, S.R., Pickens, C.V., Rosse, W.F., Howard, T.A. Ware, R.E. (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood, 95, 3589 3593.
47. Harrison, C. (2005a) Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. British Journal of Haematology, 129, 293 306.
48. Harrison, C.N. (2005b) Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncology, 1, 609 618.
49. Harrison, C.N., Donohoe, S., Carr, P., Dave, M., Mackie, I. Machin, S.J. (2002) Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thrombosis and Haemostasis, 87, 802 807.
50. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33 45.
51. Higuchi, T., Okada, S., Mori, H., Niikura, H., Omine, M. Terada, H. (1995) Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer, 75, 471 477.
52. Hultdin, M., Sundstrom, G., Wahlin, A., Lundstrom, B., Samuelsson, J., Birgegard, G. Engstrom-Laurent, A. (2007) Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 24, 63 70.
53. Ingram, W., Lea, N.C., Cervera, J., Germing, U., Fenaux, P., Cassinat, B., Kiladjian, J.J., Varkonyi, J., Antunovic, P., Westwood, N.B., Arno, M.J., Mohamedali, A., Gaken, J., Kontou, T., Czepulkowski, B.H., Twine, N.A., Tamaska, J., Csomer, J., Benedek, S., Gattermann, N., Zipperer, E., Giagounidis, A., Garcia-Casado, Z., Sanz, G. Mufti, G.J. (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 20, 1319 1321.
54. Jabbour, E., Kantarjian, H., Cortes, J., Thomas, D., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Richie, M.A., Beran, M., Giles, F. Verstovsek, S. (2007) PEG-IFN-alpha 2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer, 110, 2012 2018.
55. Jensen, M.K., de Nully, B.P., Nielsen, O.J. Hasselbalch, H.C. (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 65, 132 139.
56. Kako, S., Kanda, Y., Sato, T., Goyama, S., Noda, N., Shoda, E., Oshima, K., Inoue, M., Izutsu, K., Watanabe, T., Motokura, T., Chiba, S., Fukayama, M. Kurokawa, M. (2007) Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. American Journal of Hematology, 82, 386 390.
57. Kelaidi, C., Eclache, V. Fenaux, P. (2008) The role of lenalidomide in the management of myelodysplasia with del 5q. British Journal of Haematology, 140, 267 278.
58. Kelman, C.W., Kortt, M.A., Becker, N.G., Li, Z., Mathews, J.D., Guest, C.S. Holman, C.D. (2003) Deep vein thrombosis and air travel: record linkage study. BMJ, 327, 1072.
59. Kiladjian, J.J., Rain, J.D., Bernard, J.F., Briere, J., Chomienne, C. Fenaux, P. (2006a) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 32, 417 421.
60. Kiladjian, J.J., Cervantes, F., Leebeek, F.W.G., Chevret, S., Cazals-Hatem, D., Plessier, A., Marzac, C., Cassinat, B., Raffa, S., Garcia-Pagan, J.C., Murad, S.D., Janssen, H.L.A., Valla, D., Casadevall, N. Fenaux, P. (2006b) Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD. Blood (ASH Annual Meeting Abstracts), 108, 377.
61. Kiladjian, J.J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C. Fenaux, P. (2008) Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera. Blood, 112, 3065 3072.
62. Kodali, D., Mesa, H., Rawal, A., Cao, Q. Gupta, P. (2007) Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes. Leukaemia & Lymphoma, 48, 2375 2380.
63. Krasopoulos, G., Brister, S.J., Beattie, W.S. Buchanan, M.R. (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta analysis. BMJ, 336, 195 198.
64. Kumar, A.R., Hale, T.W. Mock, R.E. (2000) Transfer of interferon alfa into human breast milk. Journal of Human Lactation, 16, 226 228.
65. Kuter, D.J., Bain, B., Mufti, G., Bagg, A. Hasserjian, R.P. (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 139, 351 362.
66. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. Barbui, T. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114 124. (Pubitemid 38056222)
67. Lanzkron, S., Strouse, J.J., Wilson, R., Beach, M.C., Haywood, C., Park, H., Witkop, C., Bass, E.B. Segal, J.B. (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Annals of Internal Medicine, 148, 939 955.
68. varez-Larran, A., Cervantes, F., Bellosillo, B., Giralt, M., Julia, A., Hernandez Boluda, J.C., Bosch, A., Hernandez-Nieto, L., Clapes, V., Burgaleta, C., Salvador, C., rellano-Rodrigo, E., Colomer, D. Besses, C. (2007) Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia, 21, 1218 1223.
69. Lasho, T.L., Pardanani, A., McClure, R.F., Mesa, R.A., Levine, R.L., Gilliland, D.G. Tefferi, A. (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. British Journal of Haematology, 135, 683 687.
70. Lengfelder, E., Griesshammer, M. Hehlmann, R. (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leukaemia & Lymphoma, 22 (Suppl 1 135 142.
71. Lengfelder, E., Hochhaus, A., Kronawitter, U., Hoche, D., Queisser, W., Jahn-Eder, M., Burkhardt, R., Reiter, A., Ansari, H. Hehlmann, R. (1998) Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages British Journal of Haematology, 100, 15 23.
72. Leoni, F., Grossi, A. Rossi, F.P. (1983) 1-(2-Chloroethyl)-cyclohexyl- nitrosourea-induced remission in essential thrombocythemia. Acta Haematologica, 69, 180 183.
73. Liebelt, E.L., Balk, S.J., Faber, W., Fisher, J.W., Hughes, C.L., Lanzkron, S.M., Lewis, K.M., Marchetti, F., Mehendale, H.M., Rogers, J.M., Shad, A.T., Skalko, R.G. Stanek, E.J. (2007) NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth defects research. Part B, Developmental and Reproductive Toxicology, 80, 259 366.
74. Lussana, F., Caberlon, S., Pagani, C., Kamphuisen, P.W., Buller, H.R. Cattaneo, M. (2009) Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thrombosis Research, 124, 409 417.
75. Mc Lornan, D.P., Percy, M.J., Jones, A.V., Cross, N.C. Mc Mullin, M.F. (2005) Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica, 90, 1696 1697.
76. Menon, K.V., Shah, V. Kamath, P.S. (2004) The Budd-Chiari syndrome. New England Journal of Medicine, 350, 578 585.
77. Mesa, R.A. Tefferi, A. (2005) Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Seminars in Oncology, 32, 403 413. (Pubitemid 41073753)
78. Mesa, R.A., Li, C.Y., Ketterling, R.P., Schroeder, G.S., Knudson, R.A. Tefferi, A. (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single institution experience with 91 cases. Blood, 105, 973 977.
79. Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A. Tefferi, A. (2007a) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer, 109, 68 76.
80. Mesa, R.A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J.T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M.C., Wadleigh, M., Campbell, P.J., Silver, R.T., Vannucchi, A.M., Deeg, H.J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L.A., Gotlib, J., Hexner, E., Nimer, S.D., Kantarjian, H., Orazi, A., Vardiman, J.W., Thiele, J. Tefferi, A. (2007b) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 31, 737 740.
81. Mitelman, F. Heim, S. (1992) Quantitative acute leukemia cytogenetics. Genes, Chromosomes and Cancer, 5, 57 66.
82. Murakami, H., Tamura, J. Sawamura, M. (1993) MCNU in the treatment of essential thrombocythemia - a pilot study. Annals of Hematology, 66, 247 249.
83. Murphy, S., Peterson, P., Iland, H. Laszlo, J. (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Seminars in Hematology, 34, 29 39.
84. Najean, Y. Rain, J.D. (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 90, 3370 3377.
85. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472 3476.
86. Passamonti, F. Lazzarino, M. (2003) Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leukaemia & Lymphoma, 44, 1483 1488.
87. Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., Barate, C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. Lazzarino, M. (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 116, 855 861.
88. Passamonti, F., Rumi, E., Malabarba, L., Arcaini, L., Orlandi, E., Brusamolino, E., Pascutto, C., Cazzola, M. Lazzarino, M. (2004) Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Annals of Hematology, 83, 495 497.
89. Passamonti, F., Randi, M.L., Rumi, E., Pungolino, E., Elena, C., Pietra, D., Scapin, M., Arcaini, L., Tezza, F., Moratti, R., Pascutto, C., Fabris, F., Morra, E., Cazzola, M. Lazzarino, M. (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood, 110, 485 489.
90. Patel, R.K., Lea, N.C., Heneghan, M.A., Westwood, N.B., Milojkovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gaken, J., Wendon, J., Heaton, N.D. Mufti, G.J. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 130, 2031 2038.
91. Pearson, T.C., Bareford, D., Craig, J., Egan, E.L., Green, A.R., Lucas, G.S., Ludlam, C.A., McMullin, M.F., Messinezy, M., Oscier, D.G. Reilly, J.T. (1999) The management of 'low-risk' and 'intermediate-risk' patients with primary thrombocythaemia MPD (UK) Study Group. British Journal of Haematology, 106, 833 834.
92. Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., Skoda, R. Cazzola, M. (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 111, 1686 1689.
93. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., Deangelo, D.J., Clark, J.J., Lee, S.J., Golub, T.R., Wadleigh, M., Gilliland, D.G. Levine, R.L. (2006) MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Medicine, 3, e270.
94. Pinsky, P.F., Hurwitz, E.S., Schonberger, L.B. Gunn, W.J. (1988) Reye's syndrome and aspirin. Evidence for a dose-response effect. Journal of the American Medical Association, 260, 657 661.
95. Randi, M.L., Fabris, F., Varotto, L., Rossi, C., Macri, C. Girolami, A. (1990) Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P). Folia haematologica, 117, 461 467.
96. Randi, M.L., Stocco, F., Rossi, C., Tison, T. Girolami, A. (1991) Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). Journal of Medicine, 22, 213 223.
97. Robertson, B., Urquhart, C., Ford, I., Townend, J., Watson, H.G., Vickers, M.A. Greaves, M. (2007) Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 5, 1679 1685.
98. Royal College of Obstetricians and Gynaecologists 2009) Reducing the risk of thrombosis and embolism during pregnancy & the puerperium. Guideline no. 37
99. Rozman, C., Giralt, M., Feliu, E., Rubio, D. Cortes, M.T. (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 67, 2658 2663.
100. Rubin, C.M., Larson, R.A., Bitter, M.A., Carrino, J.J., Le Beau, M.M., Diaz, M.O. Rowley, J.D. (1987) Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood, 70, 1338 1342.
101. Rubin, C.M., Larson, R.A., Anastasi, J., Winter, J.N., Thangavelu, M., Vardiman, J.W., Rowley, J.D. Le Beau, M.M. (1990) t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood, 76, 2594 2598.
102. Ruggeri, M., Finazzi, G., Tosetto, A., Riva, S., Rodeghiero, F. Barbui, T. (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. British Journal of Haematology, 103, 772 777.
103. Ruggeri, M., Gisslinger, H., Tosetto, A., Rintelen, C., Mannhalter, C., Pabinger, I., Heis, N., Castaman, G., Missiaglia, E., Lechner, K. Rodeghiero, F. (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 71, 1 6.
104. Ruggeri, M., Rodeghiero, F., Tosetto, A., Castaman, G., Scognamiglio, F., Finazzi, G., Delaini, F., Mico, C., Vannucchi, A.M., Antonioli, E., V De, S., Za, T., Gugliotta, L., Tieghi, A., Mazzucconi, M.G., Santoro, C. Barbui, T. (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood, 111, 666 671.
105. Ruiz-Irastorza, G., Hunt, B.J. Khamashta, M.A. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis and Rheumatism, 57, 1487 1495.
106. Rumi, E., Passamonti, F., la Porta, M.G., Elena, C., Arcaini, L., Vanelli, L., Del, C.C., Pietra, D., Boveri, E., Pascutto, C., Cazzola, M. Lazzarino, M. (2007) Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. Journal of Clinical Oncology, 25, 5630 5635.
107. Schmitt-Graeff, A.H., Teo, S.S., Olschewski, M., Schaub, F., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U. Skoda, R.C. (2008a) JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 93, 34 40.
108. Schnittger, S., Bacher, U., Haferlach, C., Beelen, D., Bojko, P., Burkle, D., Dengler, R., Distelrath, A., Eckart, M., Eckert, R., Fries, S., Knoblich, J., Kochling, G., Laubenstein, H.P., Petrides, P., Planker, M., Pihusch, R., Weide, R., Kern, W. Haferlach, T. (2009) Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica, 94, 141 144.
109. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459 468.
110. Shaw, G.R. (2005) Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. British Journal of Haematology, 131, 180 184.
111. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, 1207 1209.
112. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood, 91, 616 622.
113. Storen, E.C. Tefferi, A. (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 97, 863 866. (Pubitemid 32154266)
114. Swerdlow, S.H. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues - IARC WHO Classification of Tumours v. 2, 2 edn.
115. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. Maciejewski, J.P. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173 2181.
116. Tam, C.S., Nussenzveig, R.M., Popat, U., Bueso-Ramos, C.E., Thomas, D.A., Cortes, J.A., Champlin, R.E., Ciurea, S.E., Manshouri, T., Pierce, S.M., Kantarjian, H.M. Verstovsek, S. (2008) The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood, 112, 1628 1637.
117. Tartaglia, A.P., Goldberg, J.D., Berk, P.D. Wasserman, L.R. (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Seminars in Hematology, 23, 172 176.
118. Terpos, E., Verrou, E., Banti, A., Kaloutsi, V., Lazaridou, A. Zervas, K. (2007) Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leukemia Research, 31, 559 562.
119. Thiele, J. Kvasnicka, H.M. (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Annals of Hematology, 82, 148 152.
120. Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der, W.J. Orazi, A. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 90, 1128 1132.
121. Toh, B.T., Gregory, S.A. Knospe, W.H. (1988) Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. American Journal of Hematology, 28, 58 60.
122. Van de Pette, J.E., Prochazka, A.V., Pearson, T.C., Singh, A.K., Dickson, E.R. Wetherley-Mein, G. (1986) Primary thrombocythaemia treated with busulphan. British Journal of Haematology, 62, 229 237.
123. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., V De, S., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. Barbui, T. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840 846. (Pubitemid 47267419)
124. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., Villani, L., Finotto, S., Ammatuna, E., Alterini, R., Carrai, V., Capaccioli, G., Di, L.S., Liso, V., Rambaldi, A., Bosi, A. Barbui, T. (2008) Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 112, 844 847.
125. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) Classification of the myeloid neoplasms. Blood, 100, 2292 2302.
126. Walker, I.D., Greaves, M. Preston, F.E., for the British Society for Haematology (2001) Investigation and management of heritable thrombophilia. British Journal of Haematology, 114, 512 528.
127. Wilkins, B.S., Erber, W.N., Bareford, D., Buck, G., Wheatley, K., East, C.L., Paul, B., Harrison, C.N., Green, A.R. Campbell, P.J. (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 111, 60 70.
128. Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159 166.
129. Young, C.W., Schochetman, G. Karnofsky, D.A. (1967) Hydroxyurea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Research, 27, 526 534.
130. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G. Fox, K.K. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine, 345, 494 502.
131. Zimmermann, N. Hohlfeld, T. (2008) Clinical implications of aspirin resistance. Thrombosis and Haemostasis, 100, 379 390.